NUVATION BIO INC

Strong Q2 2026: Nuvation Bio posts $31.7M revenue, IBTROZI® dominates ROS1‑targeted oncology sales and expands safusidenib pipeline, boosting investor confidence.

How Nuvation Bio’s $200 M convertible notes and insider sell‑offs are shaking investor confidence – what this means for its oncology pipeline and long‑term value.

Discover how Nuvation Bio, a New York‑based biopharma, is advancing next‑generation oncology drugs to tackle drug resistance and what its latest stock, governance, and investor updates reveal for patients and shareholders.

Discover Nuvation Bio Inc.’s battle against cancer drug resistance and why its stock struggles may signal deeper financial risks for investors.

Get the latest insights on Nuvation Bio’s Q4 2026 results – learn how the company’s oncology pipeline and revenue growth could shape its future profitability.

Explore how Nuvation Bio’s $13.1 M Q3 revenue surge on Ibtrozi drives new investor optimism, analyst target hikes, and future growth plans.

Discover how Nuvation Bio tackles drug‑resistant cancer with cutting‑edge oncology therapies, despite market volatility and financial hurdles.

Nuvation Bio Inc. continues to advance in oncology drug development, driven by its mission to improve patient outcomes despite market fluctuations.

Nuvation Bio Inc. has achieved a significant milestone with the FDA approval of its drug Ibtrozi, a treatment for ROS1-positive non-small cell lung cancer, positioning the company to challenge established players in the oncology market.

Nuvation Bio Inc. continues to advance in oncology drug development, despite market fluctuations, with a focus on overcoming drug resistance and improving patient outcomes.